Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05800210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

StatusRecruiting
PhasePhase 2
Started2024-05-03
View on ClinicalTrials.gov ↗

Amendment history

2026-06-02
Study Status v9
Primary completion date2026-05→2027-05
Completion date2027-05→2028-05
2025-06-12
Study Status, Contacts/Locations v8
Re-verified, no change to tracked fields
2024-09-09
Study Status, Sponsor/Collaborators v7
Collaborators1 to 2 entries
Ocala Royal Dames for Cancer Research
2024-05-07
Study Status v6
Start dateestimated 2024-05→confirmed 2024-05-03
2024-05-02
Study Status v5
Start date2024-04→2024-05
Show 4 earlier versions
2024-04-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2024-02-19
Study Status, Contacts/Locations v3
Start date2024-02→2024-04
Study sites0→1
2023-11-16
Study Status v2
Start date2023-11→2024-02
2023-09-11
Study Status v1
Start date2023-08→2023-11
2023-03-23
Original filing
University of Florida
325 trials monitored
See 23 trials at risk
Leukemia
2,553 trials monitored
See 134 trials at risk
Non-Hodgkin Lymphoma
1,512 trials monitored
See 79 trials at risk
Acute Myeloid Leukemia (AML)
1,196 trials monitored
See 63 trials at risk
and 5 more diseases
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
Trial Details
NCT Number NCT05800210
Lead Sponsor University of Florida
Collaborators: Florida Department of Health, Ocala Royal Dames for Cancer Research
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Enrollment 20 participants
Start Date 2024-05-03
Primary Completion 2027-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-04